HORIZON EUROPE
European
Scope:Specific challenge: An estimated 7.3 million Europeans between 30 and 99 years of age suffered from different types of dementias in the EU27 in 2006 (14.6 per 1 000 inhabitants), most of these being of the Alzheimer’s variety. Innovative approaches based on biomaterials can improve the treatment and prevention of neurodegenerative disorders such as Alzheimer’s disease.
Scope: Proposals should develop new multifunctional biomaterials, as part of eventual Medical Devices and Advanced Therapies, which aim to create, optimise, enhance, substitute or support preventive and therapeutic interventions in Alzheimer’s disease. They can include: biocompatible and biodegradable biomaterials as part of minimally invasive treatments, theragnostic materials, and biocompatible materials that are easily degraded/cleared after completing their roles. The development of new drug candidates for Alzheimer’s and clinical trials are excluded.
The development of new integrated experimental and computational approaches aimed to describe interface processes and their determinants should be considered as the key step for the design of safe and performing materials. Experimenta...
see more
Scope:Specific challenge: An estimated 7.3 million Europeans between 30 and 99 years of age suffered from different types of dementias in the EU27 in 2006 (14.6 per 1 000 inhabitants), most of these being of the Alzheimer’s variety. Innovative approaches based on biomaterials can improve the treatment and prevention of neurodegenerative disorders such as Alzheimer’s disease.
Scope: Proposals should develop new multifunctional biomaterials, as part of eventual Medical Devices and Advanced Therapies, which aim to create, optimise, enhance, substitute or support preventive and therapeutic interventions in Alzheimer’s disease. They can include: biocompatible and biodegradable biomaterials as part of minimally invasive treatments, theragnostic materials, and biocompatible materials that are easily degraded/cleared after completing their roles. The development of new drug candidates for Alzheimer’s and clinical trials are excluded.
The development of new integrated experimental and computational approaches aimed to describe interface processes and their determinants should be considered as the key step for the design of safe and performing materials. Experimental protocols should be planned taking due account of current good laboratory practice (GLP) and ISO guidelines. Standardisation and manufacturing processes can be addressed, including upscaling, good manufacturing practice (GMP), process analytical technology (PAT), and regulatory work in respect of relevant regulations as appropriate.
For this topic, proposals should include an outline of the initial exploitation and business plans, which will be developed further in the proposed project.
Activities expected to focus on Technology Readiness Level 5.
The Commission considers that proposals requesting a contribution from the EU between EUR 6 and 8 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Expected impact:
Improved quality of life due to minimally invasive action;
Reduced direct and indirect costs linked to the disease and its treatment;
Implementation of relevant objectives of the European Innovation Partnership on Active and Healthy Ageing (COM (2012) 83).
Type of action: Research & Innovation Actions
see less
Consortium characteristics
:
The aid is European, you can apply to this line any company that is part of the European Community.
characteristics of the Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Characteristics of financing
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme.
Evaluation
3.1 Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme, with the following exceptions:
For single-stage and second-stage evaluations, the threshold for the criteria Excellence and Impact will be 4. The overall threshold, applying to the sum of the three individual scores, will be 12.
In case of equal overall scores in the ranked list, the priority order of proposals will be established in accordance with part H of the General Annexes, except that proposals will be ranked on the basis of individual scores for the Impact criterion before the Excellence criterion.
3.2 Guide to the submission and evaluation process
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
Indicative timetable for evaluation and grant agreement:
Information on the outcome of two-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 months from... Please read carefully all provisions below before the preparation of your application.
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme.
Evaluation
3.1 Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme, with the following exceptions:
For single-stage and second-stage evaluations, the threshold for the criteria Excellence and Impact will be 4. The overall threshold, applying to the sum of the three individual scores, will be 12.
In case of equal overall scores in the ranked list, the priority order of proposals will be established in accordance with part H of the General Annexes, except that proposals will be ranked on the basis of individual scores for the Impact criterion before the Excellence criterion.
3.2 Guide to the submission and evaluation process
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
Indicative timetable for evaluation and grant agreement:
Information on the outcome of two-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
Annotated Model Grant Agreement
Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.
Financial support to Third Parties – where a topic description foresees financial support to Third Parties, these provisions apply.
Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Additional information about the call
other advantages
